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Background
Heart transplantation is the therapy of choice for
advance heart failure. Our group developed two trans-
plant programs at Instituto Nacional del Torax and
Clinica Davila. We report our clinical experience based
with generic immunosuppression with may have lower
costs and may allow more patients to be transplanted.
Methods
Fifty-three consecutive patients were transplanted
between November 2008 and April 2013, representing
51% of all Chilean cases.
Results
Ischemic or dilated cardiomyopathy were the main indi-
cations (23(43%) each), age 48+13 years and 48(91%)
were male. Transplant listing Status: IA 14(26%)(VAD or
2 inotropes), IB 14(26%)(1 inotrope) and II 25 (47%) (no
inotrope). Mean waiting time 70+83 days. Twelve (24%)
were transplanted during VAD support (median support:
36 days). Operative technique: orthotopic bicaval
transplant with ischemia time: 175+54 min. Operative
mortality: 3 (6%), all due to right ventricular failure.
Re-exploration for bleeding 2 (4%), stroke 3(6%), medias-
tinitis 0(0%), pneumonia 4(8%), and transient dialysis
6 (11%). Mean follow-up was 21+14 months. Three-year
survival was 86+6%. One patient died of Pneumocystis
Jirovecii pneumonia and the other died suddenly (non-
compliance). Freedom from rejection requiring specific
therapy was 80+7% at 3 years of follow-up. Four hundred
eighty four endomyocardial biopsies were done: 11(2.3%)
had 2R rejection. All survivors are in NYHA (New York
Heart Association) functional class I and all but one has
normal biventricular function.
Conclusion
Mid-term results are similar to those reported by the
registry of the International Society for Heart and Lung
Transplantation. Rejection rates are low in spite of gen-
eric immunosuppression.
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